<DOC>
	<DOCNO>NCT01649817</DOCNO>
	<brief_summary>This multicenter , retrospective observational study evaluate compliance reason withdrawal patient moderate severe active rheumatoid arthritis treatment intravenous RoActemra/Actemra ( tocilizumab ) daily clinical practice . Data collect eligible patient period 6 month .</brief_summary>
	<brief_title>A Retrospective Observational Study Compliance Patients With Rheumatoid Arthritis Treatment With RoActemra/Actemra ( Tocilizumab ) Clinical Practice ( REMISSION II )</brief_title>
	<detailed_description />
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis , Rheumatoid</mesh_term>
	<criteria>Adult patient , &gt; /= 18 year age Moderate severe rheumatoid arthritis accord revised 1987 ACR criterion baseline RoActemra/Actemra treatment must initiate 6 month prior ICF sign Patient eligible accord summary product characteristic ( SPC ) routine clinical practice/European recommendation use biologic DMARDs treatment rheumatoid arthritis Rheumatic autoimmune disease RA Participation interventional clinical trial observational period</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>